TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03541434

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete Blood Count
Description: White blood cell subgroups count

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete Blood Count
Description: White blood cell subgroups count

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete Blood Count
Description: White blood cell subgroups count

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete Blood Count
Description: White blood cell subgroups count

Intervention type: DIAGNOSTIC_TEST
Intervention: Tympanometry
Description: Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance

Intervention type: DIAGNOSTIC_TEST
Intervention: Tympanometry
Description: Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance

Intervention type: DIAGNOSTIC_TEST
Intervention: Tympanometry
Description: Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance

Intervention type: DIAGNOSTIC_TEST
Intervention: Tympanometry
Description: Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance

Intervention type: PROCEDURE
Intervention: Tonsillectomy and/or adenoidectomy
Description: Excision of palatine and/or pharyngeal tonsils.

Intervention type: PROCEDURE
Intervention: Tonsillectomy and/or adenoidectomy
Description: Excision of palatine and/or pharyngeal tonsils.

Intervention type: PROCEDURE
Intervention: Tonsillectomy and/or adenoidectomy
Description: Excision of palatine and/or pharyngeal tonsils.
Study: NCT02095405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.~AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SVT group: Oral tablets of placebo prior to the electrophysiology study in patients with SVT.~AF group: White chocolate and Decaffeinated substances in patients with AF at the time of Ambulatory monitoring.
Study: NCT03943823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen vaginal cream
Description: Either Premarin or Estrace cream will be used (dependent on patient's insurance). Premarin 1 gram every night for the first 7 days, then 0.5 grams twice weekly. Estrace cream 2 grams daily for first 7 days, then 1 gram twice-weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimo-San vaginal gel
Description: Half applicator for three times a week for 1st week, then half applicator for 2 times a week.
Study: NCT04812405

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Trios4
Description: Examination of occlusal surfaces with 3D scanner and optical criteria
Study: NCT02622087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-Session-Treatment
Description: There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-Session-Treatment
Description: There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-Session-Treatment
Description: There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.
Study: NCT02254122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat®

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat®
Study: NCT00201617

Intervention type: DEVICE
Intervention: Bone-anchored hearing aid
Study: NCT00841308

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision to start and titrate drug treatment based only on home blood pressure monitoring
Description: Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision to start and titrate drug treatment based only on home blood pressure monitoring
Description: Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm).
Study: NCT00853879

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid, Vitamin B6, Vitamin B12
Description: Intervention #1. A combination of the following vitamin supplements: 2.5mg of folate, 25mg of vitamin B6 and 2mg of vitamin B12. This combination will be described as triple therapy with folate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B6, B12, L-methylfolate
Description: Intervention #2. A combination of the following vitamin supplements: 2.8mg of L-methylfolate, 25 mg of vitamin B6 and 2mg of vitamin B12.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: B6, B12, Placebo
Description: Intervention #3. A combination of the following vitamin supplements: 25mg of vitamin B6 and 2mg of vitamin B12 without supplementary folate or L-methylfolate. This combination will be described as triple therapy with placebo
Study: NCT04436705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) technique
Description: The PMR technique utilized in this study was based on the original technique designed by Jacobson (1938) and subsequently modified by Bernstein and Borkovec (1973). The PMR technique involves tensing the individual muscle groups for about 5 seconds for each muscle. Then, allowing them to relax for about 10 seconds, and notice how the muscle feels when it is relaxed in contrast to how it felt when it was tensed. The technique is accompanied by breathing exercises in order to feel the sense of relaxation. In this study, the PMR technique refers to tensing and relaxing the muscles from the forehead to the feet one by one, including the eleven muscle groups (right arm, left arm, forehead, jaw and neck, back and shoulders, stomach, thighs, right calf, left calf, right foot and left foot). The total procedure takes around 20 minutes.
Study: NCT02253732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 months exercise intervention program
Description: 3 months exercise intervention program which is given 3-times per week, 60 min session duration, 65-75% repetition maximum or heart rate maximum, combined strength \& aerobic exercises
Study: NCT00387049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity Program for Smoking Cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety Sensitivity Program for Smoking Cessation
Study: NCT01991899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR Bio-Manguinhos
Description: 1170 children will receive 100% produced by Bio-Manguinhos, 3 diferents lots. Application of a 0.5 ml dose, subcutaneous 390 children will receive 0,5 ml, subcutaneous, MMR GlaxoSmithKline

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR GlaxoSmithKline
Description: 390 children will receive 0,5 ml MMR GlaxoSmithKline
Study: NCT02423668

Intervention type: PROCEDURE
Intervention: 50% Partial adjustment
Description: Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.

Intervention type: PROCEDURE
Intervention: No adjustment
Description: IOL power selection for the second eye irrespective of first eye prediction error

Intervention type: PROCEDURE
Intervention: Full adjustment
Description: Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
Study: NCT04484844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOKUYAMA SHIELD FORCE PLUS
Description: Self-reinforcing (SR) monomer technology

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride 5% Dental Varnish
Description: 5% NaF
Study: NCT02204358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow stem cells
Description: Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.~If patients agree to participate, they will receive a bone marrow stem cells collection and separation of adhesions by hysteroscopy surgery. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. According to the endometrial conditions, the doctor will select an appropriate time for pregnancy and follow-up. The doctor may also require patients to do some unscheduled visits.
Study: NCT06730178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation training
Description: The training tapes used were meditation relaxation training tapes translated form Jacobson progressive relaxation technique with copyrights. The tapes were recorded by a male therapist. Participants were instructed to perform the treatment in the evening, preferably just before bedtime, total time was 15 minutes.
Study: NCT01442727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium selenite
Description: 200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
Study: NCT00417638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular cooling by the Celsius Control System

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Study: NCT01725360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
Study: NCT02364154

Intervention type: OTHER
Intervention: Control group-Blood sampling
Description: Determine the metabolic phenotype of blood plasma by NMR spectroscopy

Intervention type: OTHER
Intervention: Control group-Blood sampling
Description: Determine the metabolic phenotype of blood plasma by NMR spectroscopy

Intervention type: OTHER
Intervention: Blood sampling
Description: determine amount and type of free circulating miRNA in blood plasma

Intervention type: OTHER
Intervention: Blood sampling
Description: determine amount and type of free circulating miRNA in blood plasma
Study: NCT00919542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: prednisolone 40mg daily then reducing regimen over 16 weeks
Study: NCT02634983

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QVA149
Description: QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03728998

Intervention type: OTHER
Group type: OTHER
Intervention: Passive leg raise (PLR)
Description: A PLR will simulate an autotransfusion of 250-300 cc.~* 1. Starting in semi-succumbed position (45 degree head-up)~* 2. PLR is performed by lowering head-end and putting a for this purpose designed device of 45 degrees under the patients legs. The PLR is non-invasive.

Intervention type: OTHER
Group type: OTHER
Intervention: Clearsight non-invasive hemodynamic monitoring system
Description: 3 baseline readings will be done for CO, CI, SV and SVR, separated by one minute intervals. Subsequently, the standardized passive leg-raise test will be performed and measurements of CO, CI, SV and SVR will be repeated at 30, 60, 90 and 120 seconds. Then the patient is repositioned to his original position, and after two minutes another reading of CO, CI, SV and SVR is done. Then all patients will receive a fluid challenge of 500cc natriumchloride 0.9% IV, considered as normal treatment/ common practice in our ED. 120 seconds after finishing the fluid challenge the final reading of CO, CI, SV and SVR is done.
Study: NCT04008264

Intervention type: DRUG
Intervention: Scopolamine Patch (Transderm V)
Description: During the observational phase, patients will be given a prescription for an 18 day supply of scopolamine, and patients will record the same data as prior to the intervention.
Study: NCT02741258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepitel Film
Description: Placement of Mepitel Film to prevent skin toxicity
Study: NCT03900221

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04072731

Intervention type: OTHER
Intervention: pathologic
Description: All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.

Intervention type: OTHER
Intervention: pathologic
Description: All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.
Study: NCT01491269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavioural treatment
Description: Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
Study: NCT02428894

Intervention type: DEVICE
Intervention: LVAD
Study: NCT01310244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat, Carboplatin, Paclitaxel
Description: Up to 6 cycles of combination therapy of belinostat plus carboplatin (AUC 6) and paclitaxel 200 mg/m2. Initial dose of belinostat will be 1000mg/m2 for MTD dose escalation evaluation.
Study: NCT00493987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate
Description: testosterone ester

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dutasteride
Description: 5 alpha-reductase inhibitor
Study: NCT04346771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Positive ABMT
Description: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
Study: NCT02234336

Intervention type: PROCEDURE
Intervention: Noncontrast echocardiography

Intervention type: PROCEDURE
Intervention: Contrast Echocardiography
Study: NCT02741258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: skin cream
Description: cream to treat skin erythema due to radiotherapy
Study: NCT00808899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection of Primary Tumor
Description: Surgical Resection of Primary Tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC
Description: Peripheral Blood Stem Cell Harvest
Study: NCT02234336

Intervention type: PROCEDURE
Intervention: Cardiac magnetic resonance imaging
Study: NCT03268512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-PRF
Description: Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A-PRF
Description: Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days.
Study: NCT00475878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: 10mg escitalopram/day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule/day for 3 months
Study: NCT01633086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitric oxide gel
Description: 1. st gel: sodium nitrites,BID local use X 28 days~2. nd gel: maleic/ascorbic acids ,BID local use X 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: placebo gel,BID local use X 28 days
Study: NCT00552786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: 600mg twice daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glucose
Description: 1 gm glucose capsule
Study: NCT00429494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: 22.5 mg IM injection 2 months before transplant and 3 months post-transplant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires taking about 15 minutes to complete.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Stem cell infusion on Day 0.
Study: NCT04263792

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]fluoropropyl-trimethoprim
Description: \[18F\]Fluoropropyl-Trimethoprim, also known as \[18F\]F-TMP, is a radiolabeled imaging agent for positron emission tomography (PET/CT).The use most relevant to this protocol is for imaging bacterial infection in human subjects. The parent compound, trimethoprim (TMP) is a well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder. An immediate clinical use for TMP radiotracers is imaging of pathologic bacteria that are the cause of human infection.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]fluoropropyl-trimethoprim
Description: \[18F\]Fluoropropyl-Trimethoprim, also known as \[18F\]F-TMP, is a radiolabeled imaging agent for positron emission tomography (PET/CT).The use most relevant to this protocol is for imaging bacterial infection in human subjects. The parent compound, trimethoprim (TMP) is a well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder. An immediate clinical use for TMP radiotracers is imaging of pathologic bacteria that are the cause of human infection.